Free Technical Research on IsoRay and Three More Medical Supplies Equities
Stock Research Monitor: STAA, CFMS, and IART
LONDON, UK / ACCESSWIRE / July 23, 2018/ If you want a free Stock Review on ISR sign up now at www.wallstequities.com/registration. On Friday, July 20, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. US markets saw five out of nine sectors finishing the day in green and four in red. Taking into consideration last Friday's market sentiment, WallStEquities.com assessed the following Medical Instruments & Supplies equities this morning: IsoRay Inc. (NYSE AMER: ISR), STAAR Surgical Co. (NASDAQ: STAA), Conformis Inc. (NASDAQ: CFMS), and Integra LifeSciences Holdings Corp. (NASDAQ: IART). All you have to do is sign up today for this free limited time offer by clicking the link below.
www.wallstequities.com/registration
IsoRay
On Friday, shares in Richland, Washington-based IsoRay Inc. recorded a trading volume of 570,207 shares. The stock ended at $0.53, declining 1.78% from the last trading session. The Company's shares have gained 13.66% in the last month and 21.40% over the previous three months. The stock is trading above its 50-day and 200-day moving averages by 4.87% and 14.97%, respectively. Furthermore, shares of IsoRay, which through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the US, have a Relative Strength Index (RSI) of 49.23. Get the full research report on ISR for free by clicking below at:
www.wallstequities.com/registration/?symbol=ISR
STAAR Surgical
Monrovia, California headquartered STAAR Surgical Co.'s stock finished last Friday's session flat at $33.90. A total volume of 203,954 shares was traded. The Company's shares have gained 102.39% over the previous three months and 229.13% in the last twelve months. The stock is trading above its 50-day and 200-day moving averages by 14.69% and 78.66%, respectively. Furthermore, shares of STAAR Surgical, which together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and delivery systems to deliver the lenses into the eye, have an RSI of 70.10. Get access to our top-rated research, including the free report on STAA at:
www.wallstequities.com/registration/?symbol=STAA
Conformis
At the close of trading on Friday, shares in Billerica, Massachusetts headquartered Conformis Inc. saw a drop of 2.83%, ending the day at $1.03. The stock recorded a trading volume of 527,215 shares, which was higher than its three months average volume of 473.07 thousand shares. The stock is trading below its 50-day moving average by 19.66%. Moreover, shares of Conformis, which develops, manufactures, and sells joint replacement implants, have an RSI of 31.69. Click here to subscribe for a free membership which welcomes you with our report on CFMS at:
www.wallstequities.com/registration/?symbol=CFMS
Integra LifeSciences Holdings
Plainsboro, New Jersey headquartered Integra LifeSciences Holdings Corp.'s shares ended the day 0.43% lower at $62.95 with a total trading volume of 551,043 shares. The stock has gained 12.01% in the previous three months and 13.02% over the last twelve months. The Company's shares are trading above their 200-day moving average by 14.30%. Additionally, shares of Integra LifeSciences, which develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery, have an RSI of 44.20.
On July 02nd, 2018, research firm Citigroup downgraded the Company's stock rating from 'Buy' to 'Neutral'. To get free access to your research report on IART, sign up at:
www.wallstequities.com/registration/?symbol=IART
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
https://wallstequities.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@wallstequities.com
Phone number: 21 32 044 483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Wall St. Equities
